(19) World Intellectual Property Organization

International Bureau



1 (1888 - 1988) | 1 (1888 - 1881) 1 (1888 - 1888 - 1888 - 1888 - 1888 - 1888 - 1888 - 1888 - 1888 - 1888 - 188

(43) International Publication Date 17 February 2005 (17.02.2005)

(10) International Publication Number WO 2005/013975 A1

(51) International Patent Classification7: C07D 209/42, A61P 3/12

A61K 31/404,

(21) International Application Number:

PCT/GB2004/003364

(22) International Filing Date: 4 August 2004 (04.08.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0318464.5

7 August 2003 (07.08.2003)

SK10 4TG (GB). WHITTAMORE, Paul, Robert, Owen [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

- (74) Agent: ASTRAZENECA; Global Intellectual Property, S-151 85 Sodertalje (SE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

$$(\mathbb{R}^4)_m$$

$$(\mathbb{R}^4)_m$$

$$(\mathbb{R}^1)_n$$

$$(\mathbb{R}^1)_n$$

(30) Priority Data:
0318464.5 7 August 2003 (07.08.2003) GB

(71) Applicant (for all designated States except MG, US): ASTRAZENECA AB (SEVSE); Sodertalje, S-151 85 (SE).

(71) Applicant (for MG only): ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London, Greater London W1k ILN (GB).

(72) Inventors, and (73) Inventors, and (74) Inventors/Applicants (for US only): BIRCH, Alan, Martin (GB/GB); AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). GODFREY, Linda (BB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). GODFREY, Linda (BB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). SUDPRON, Linda (BB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). SUDPRON, Linda (BB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). SUDPRON, Linda (BB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). SUDPRON, Linda (BB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). SUDPRON, Linda (BB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). SUDPRON, Linda (BB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). SUDPRON, Linda (BB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). SUDPRON, Linda (BB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). SUDPRON, Linda (BB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). SUDPRON, Linda (BB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). SUDPRON, Linda (BB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). SUDPRON, Linda (BB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). SUDPRON, Linda (BB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4 and -S(O)_CR² (wherein c is 0, 1 or 2); compounds which possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described.